Cencora Options Signal Caution Ahead of Tuesday Print

Options positioning is the sharpest signal into COR's November 4 results, with put demand running well above its recent norm despite a stock that has largely been left alone by short sellers.

The put/call ratio closed at 0.42 on October 30, more than three standard deviations above its 20-day average of 0.36. That is an unusually large gap for a name where the ratio has rarely strayed far from that average, and it has arrived just as the stock posted a 7.6% gain over the past month to $330.84. The borrow market tells a different story entirely: short interest has fallen roughly 14% over the past month to just 2% of free float, cost to borrow is a negligible 0.46%, and availability is effectively unconstrained. There is no meaningful short pressure here. The options skew is a hedge, not a coordinated bear thesis.

Analyst activity in the run-up has leaned constructively. Morgan Stanley raised its target to $377 from $346 on October 30, maintaining its Overweight rating, while Argus Research lifted to $380 and Leerink Partners nudged to $388 earlier in the month. UBS cut its target to $400 from $430 in mid-October but kept its Buy rating, an acknowledgment of near-term caution rather than a change of view. The consensus mean target sits at $372, roughly 12% above the current price. EPS momentum ranks in the 94th percentile over the past 30 days, and the analyst recommendation differential ranks equally high, suggesting the Street has been revising estimates upward into the print. The one caveat is forward EPS growth, which ranks only in the 37th percentile on a year-over-year basis, a reminder that the distribution business runs on thin margins where volume and pricing mix matter more than headline revenue.

The most notable ownership detail is Walgreens Boots Alliance, which filed a Schedule 13D activist disclosure earlier this year and has since trimmed its stake to 4.96% from 5.4% as of its June 2025 filing. That filing is now stale, and under standard 13D rules a holder falling below 5% may not file again, so the current position is unknown. JP Morgan Asset Management added over 1.2 million shares in the quarter to September, and T. Rowe Price added roughly 926,000 shares over the same period, two of the larger institutional moves on record. Insider activity has run net negative over the past 90 days, with an EVP selling $3.7 million in late August outside of a pre-arranged plan, though the scale is modest relative to the company's $63 billion market cap.

Wikipedia attention for Cencora is running at a two-standard-deviation spike relative to its own 90-day history, an ORTEX Alt Data signal that tracks retail engagement rather than fundamentals. With no measured alt-data lead available for this name, that attention reading is colour only. Tuesday's print will test whether a month of price gains and rising analyst targets can survive scrutiny of margins and specialty drug volumes in a quarter where the put market, at least, is priced for more uncertainty than usual.